Private hospital operator Mediclinic, recently delisted from the JSE by a Remgro-led consortium, has opted not to pay a final dividend for the year to end-March to prevent reducing the multibillion-rand acquisition price paid by the consortium.
“The group’s dividend policy before the acquisition was to target a payout ratio of between 25% and 35% of full-year adjusted earnings. Mediclinic’s board may revise the policy at its discretion,” Remgro said on Thursday...A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and TimesLive Premium.
Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen: